PCSK9: an emerging target for treatment of hypercholesterolemia. - sprookjes - yvandenbroek - TriplyDB

PCSK9: an emerging target for treatment of hypercholesterolemia.

PCSK9: an emerging target for treatment of hypercholesterolemia.

http://www.wikidata.org/entity/Q37825903

about

Mechanisms and genetic determinants regulating sterol absorption, circulating LDL levels, and sterol elimination: implications for classification and disease risk Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms.A Mechanistic Systems Pharmacology Model for Prediction of LDL Cholesterol Lowering by PCSK9 Antagonism in Human Dyslipidemic Populations Familial hypercholesterolemia: the lipids or the genes?Targeted In Situ Gene Correction of Dysfunctional APOE Alleles to Produce Atheroprotective Plasma ApoE3 Protein.Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels.The facts behind niacin.Treatment of familial hypercholesterolemia: is there a need beyond statin therapy?Making sense of therapeutics using antisense technology.Anti-PCSK9 therapies for the treatment of hypercholesterolemia.Evaluation of proprotein convertase subtilisin/kexin type 9: focus on potential clinical and therapeutic implications for low-density lipoprotein cholesterol lowering.Proprotein convertases subtilisin/kexin type 9, an enzyme turned escort protein: hepatic and extra hepatic functions.PCSK9 and resistin at the crossroads of the atherogenic dyslipidemia.Targeting LDL Cholesterol With LNA.Clinical Application of Genetic Testing in Heart Failure.

P2860

Q27003094-14167A08-E774-4DFF-AB97-EE714A0FEFC2 Q33970677-DB3D1148-2454-4E5D-99C3-A9C7AD4CCFDA Q34658086-8CE9CF50-0C69-470E-8D5F-39DD0E83AA7B Q35014525-E531AAA5-F023-43FC-9564-642C9F9A764F Q35974993-429B2538-32DE-468E-BC23-8710F86A5F1F Q36481769-5E027FC6-0E69-4FE5-A7E3-506F33960BF1 Q37926768-BFD3B4B7-A796-4655-A502-9DA5A5D33AB6 Q37963825-C8E3918D-BEB0-457E-B9B4-1C4331A15EDD Q38014478-0ACE3D54-B158-4075-BA9F-0FE0A4012B07 Q38067460-A34BDB5D-C6A8-4254-A31B-00F38ED973F1 Q38095872-F5F63F9B-0C56-4869-89F9-ACBA0CC0E6D8 Q38109960-98E7B326-5065-4866-8063-A077F2DD0DE2 Q38153456-F65A82A8-E693-4707-AFC2-ABE415E2E1EF Q41952644-C1F29671-77B2-4BAF-9FDC-80B2FB17F874 Q50074149-6C82C0E9-9C0B-4149-AE44-4B8C6EAF3931

P2860

PCSK9: an emerging target for treatment of hypercholesterolemia.

http://www.wikidata.org/entity/Q37825903

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 05 January 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

PCSK9: an emerging target for treatment of hypercholesterolemia.

@en

PCSK9: an emerging target for treatment of hypercholesterolemia.

@en-gb

PCSK9: an emerging target for treatment of hypercholesterolemia.

@nl

type

label

PCSK9: an emerging target for treatment of hypercholesterolemia.

@en

PCSK9: an emerging target for treatment of hypercholesterolemia.

@en-gb

PCSK9: an emerging target for treatment of hypercholesterolemia.

@nl

prefLabel

PCSK9: an emerging target for treatment of hypercholesterolemia.

@en

PCSK9: an emerging target for treatment of hypercholesterolemia.

@en-gb

PCSK9: an emerging target for treatment of hypercholesterolemia.

@nl

P1433

Q37825903-A17D8D1B-F308-455D-B722-40559330D52C

P1476

Q37825903-286EA7E2-A4DE-488B-B04F-9EC6197D1BF0

P2093

Q37825903-BC072F34-6F0F-41EC-BE60-6010F71D82EE

P2860

Q37825903-05C3EC4F-BCB7-4496-B7CA-61E9464E154F

Q37825903-07451AB3-F616-490E-A94A-55E2526E07E5

Q37825903-09C9F90D-7D37-41B3-BDF1-ECC73E380E39

Q37825903-0B2A1E49-331E-4405-8DB5-4D8F86DE887C

Q37825903-0E370C93-2B75-44DD-BC9D-EC189845E966

Q37825903-17043052-B565-4AB9-B974-972849B21D23

Q37825903-1C5478BA-0439-426D-BC7D-B5FBE661603B

Q37825903-1FD15ED8-B451-4ACC-B243-26ECE6A3C756

Q37825903-1FD301F1-A957-4FBA-A672-60D0A51DEAC8

Q37825903-25817817-24E0-4718-9665-4A4004421606

P304

Q37825903-D278E665-EB99-4A8C-B7D5-5128BFE77105

P31

Q37825903-0B2FC4DD-C430-412E-B819-996039C8725C

Q37825903-dcb9c88e-05ac-439f-ba7b-96f373536126

P356

Q37825903-946F6714-7A34-45FF-B1D8-886D7FBACA76

P407

Q37825903-531B6583-20B2-4089-9C37-69BE95CC529C

P433

Q37825903-A3F11136-FBEB-4338-B0FC-4474E8751B29

P478

Q37825903-1F7B65CB-33FF-4DA3-8E19-E81D00FD887A

P50

Q37825903-6944FAEA-8B7E-4918-A8DE-B7266F08A4EA

P577

Q37825903-AB9D3122-3238-40E7-9720-25C56873C3C9

P698

Q37825903-98455C57-1F2F-49B3-9038-F7EFE67A0C2F

P921

Q37825903-753B42ED-F333-4C23-AB0B-0A2DE3F9E69B

P356

14728222.2011.547480

P1433

Expert Opinion on Therapeutic Targets

P1476

PCSK9: an emerging target for treatment of hypercholesterolemia.

@en

P2093

Christopher J Duff

http://www.w3.org/2001/XMLSchema#string

P2860

A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo

The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation

Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly

The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications

Functional characterization of Narc 1, a novel proteinase related to proteinase K

The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2

Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation

The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR

Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice

Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels

P304

157-168

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14728222.2011.547480

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Nigel M. Hooper

P577

2011-01-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21204732

http://www.w3.org/2001/XMLSchema#string

P921

hypercholesterolemia